Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 374

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Clinical uses of intravenous immunoglobulin

Open access
Jolles, S, Sewell, W A C, Misbah, S A·2005·Clinical and Experimental Immunology

Abstract

Intravenous immunoglobulin (IVIG) is a blood product prepared from the serum of between 1000 and 15 000 donors per batch. It is the treatment of choice for patients with antibody deficiencies. For this indication, IVIG is used at a ‘replacement dose’ of 200–400 mg/kg body weight, given approximately 3-weekly. In contrast, ‘high dose’ IVIG (hdIVIG), given most frequently at 2 g/kg/month, is used as an ‘immunomodulatory’ agent in an increasing number of immune and inflammatory disorders. Initial use of hdIVIG was for immune thrombocytopenic purpura (ITP) in children [1]. The clinical specialities using the largest amounts of IVIG are neurology, haematology, immunology, nephrology, rheumatology and dermatology. IVIG has had a major impact on the treatment of neurological disorders including dermatomyositis, Guillain–Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), myasthenia gravis and stiff person syndrome. In haematology it is used to treat immune cytopenias, parvovirus B19 associated red cell aplasia, hypogammaglobulinaemia secondary to myeloma and chronic lymphatic leukaemia and post-bone marrow transplantation. In immunology IVIG is used in the treatment of primary antibody deficiency (PAD), in nephrology, rheumatology and ophthalmology it has been used to treat vasculitis, systemic lupus erythematosis (SLE), mucous membrane pemphigoid and uveitis and in dermatology it is used most commonly to treat Kawasaki syndrome, dermatomyositis, toxic epidermal necrolysis and the blistering diseases (Table 1). Major uses of intravenous imunoglobulin (IVIG). IVIG is used mainly at high dose (2 g/kg) for the indications listed in neurology, haematology, rheumatology, dermatology and others while in immunology replacement doses (0·4 g/kg) are given. The uses listed are not exhaustive, but aim to cover the disorders for which IVIG is most frequently used and whether a randomized controlled (RCT) study or Cochrane review (CR) is available. CVID, common variable immunodeficiency; XLA, X-linked agammaglobulinaemia; HIGM, hyper-IgM syndrome; WAS, Wiskott Aldrich syndrome; CLL, chronic lymphocytic leukaemia. *Blistering diseases include pemphigus vulgaris, pemphigus folaceous, bullous and nodular pemphigoid, mucous membrane pemphigoid, gestational pemphigoid, epidermolysis bullosa acquisita and linear IgA disease. Major uses of intravenous imunoglobulin (IVIG). IVIG is used mainly at high dose (2 g/kg) for the indications listed in neurology, haematology, rheumatology, dermatology and others while in immunology replacement doses (0·4 g/kg) are given. The uses listed are not exhaustive, but aim to cover the disorders for which IVIG is most frequently used and whether a randomized controlled (RCT) study or Cochrane review (CR) is available. CVID, common variable immunodeficiency; XLA, X-linked agammaglobulinaemia; HIGM, hyper-IgM syndrome; WAS, Wiskott Aldrich syndrome; CLL, chronic lymphocytic leukaemia. *Blistering diseases include pemphigus vulgaris, pemphigus folaceous, bullous and nodular pemphigoid, mucous membrane pemphigoid, gestational pemphigoid, epidermolysis bullosa acquisita and linear IgA disease. In this paper, we review recent developments in the understanding of mechanisms of action of IVIG, the major current clinical areas of use concentrating on conditions with a better established evidence base and discuss emerging areas of use of IVIG. The mechanisms of action of therapeutic immunoglobulin are complex, but over recent years important advances in understanding have been made (summarized in Fig. 1) [2]; the predominant mechanism operating in a particular situation appears to depend on both the immunoglobulin dose and the pathogenesis of the disease under consideration. Immunomodulatory actions of intravenous immunoglobulin. Intravenous immunoglobulin (IVIG), may for the purposes of understanding, be thought of as four separate components: (1) actions mediated by the variable regions F(ab′)2, (2) actions of Fc region on a range of Fc receptors (FcR), (3) actions mediated by complement binding within the Fc fragment and (4) immunomodulatory substances other than antibody in the IVIG preparations. It should be remembered that not all the potential mechanisms of action fit perfectly into the groupings and that several mechanisms may act concurrently (TCR, T cell receptor; ADCC, antibody dependent cellular cytotoxicity; DC, dendritic cell). Commercial IVIG preparations contain a ‘species repertoire’ of antibody specificities, resulting in neutralization of a wide range of antigens including pathogens and superantigens [3]; there is, however, significant batch-to-batch variation in the concentration of a particular antibody [4]. IVIG has been shown to have a considerable inhibitory effect on mitogen-induced T cell proliferation in vitro[5]. This effect has been shown for intact IgG, with less evidence for a role for Fc fragment [6]. Both antigen-dependent

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2249.2005.02834.x

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Cited by

See all 374

Metadata

Authors
Jolles, S., Sewell, W. A. C., & Misbah, S. A.
Venue
Clinical and Experimental Immunology
Published
2005-06-16
Volume
142
Issue
1
Pages
1-11
ISSN
  • 0009-9104 (ISSN-L)
  • 1365-2249
OpenAlex
W2104373525
Cited by
374
References
65
FWCI
5.04
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical uses of intravenous immunoglobulin. https://app.cochat.ai/papers/10.1111/j.1365-2249.2005.02834.x
The paper
Jolles, S., Sewell, W. A. C., & Misbah, S. A. (2005). Clinical uses of intravenous immunoglobulin. Clinical and Experimental Immunology. https://doi.org/10.1111/j.1365-2249.2005.02834.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.